Ming Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ming Lu has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Hoffstrom
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
79 shared publications - Dennis J. Slamon
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
79 shared publications - John A. Glaspy
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
79 shared publications - Jun Zhang
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
79 shared publications - KeWei Gong
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California
79 shared publications - Leonard Presta
Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California
79 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF14
Topoisomerase-Based CDH17 Antibody–Drug Conjugates Overcome P-gp Resistance but Undergo Target-Mediated Clearance in Colorectal Cancer
Purpose: Cadherin 17 (CDH17) is an emerging therapeutic target in colorectal cancer; however, the effects of drug efflux and physiologic CDH17 expression on the activity and pharmacokinetics (PK) of CDH17-directed antibody–drug conjugates (ADC) remain poorly understood. We evaluated the impact of payload selection and target-mediated clearance on CDH17-directed ADCs. Experimental Design: CDH17-directed ADCs carrying either monomethyl auristatin E (MMAE) or the topoisomerase 1 inhibitor exatecan were evaluated in colorectal cancer models with variable P-glycoprotein (P-gp) expression. The effects of P-gp modulation on ADC sensitivity were assessed. CDH17 expression in human tissues was characterized by immunohistochemistry (IHC), and PK studies were performed in cynomolgus monkeys and mice engineered to express human CDH17. Results: CDH17-exatecan ADCs demonstrated greater antitumor activity than CDH17-MMAE ADCs in P-gp–expressing colorectal cancer models. Forced P-gp expression induced resistance to CDH17–MMAE ADCs without affecting sensitivity to CDH17-exatecan ADCs, whereas genetic or pharmacologic inhibition of P-gp restored CDH17–MMAE activity. CDH17 was highly expressed in colorectal cancer and localized to the lateral membranes of gastrointestinal (GI) epithelial cells in normal tissues. In mice expressing human CDH17, CDH17-directed antibodies and ADCs exhibited approximately fourfold faster clearance than in wild-type (WT) mice or cynomolgus monkeys, consistent with substantial target-mediated systemic drug clearance. Conclusions: Together, these findings identify topoisomerase 1 inhibitor payloads, such as exatecan, as advantageous for targeting P-gp–expressing colorectal cancers while highlighting target-mediated clearance and potential on-target, off-tumor toxicity as important translational challenges for CDH17-directed therapeutics and other ADCs targeting antigens with substantial normal tissue expression.
- 27 October 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF14
Open AccessTopoisomerase-Based CDH17 Antibody–Drug Conjugates Overcome P-gp Resistance but Undergo Target-Mediated Clearance in Colorectal Cancer
Purpose: Cadherin 17 (CDH17) is an emerging therapeutic target in colorectal cancer; however, the effects of drug efflux and physiologic CDH17 expression on the activity and pharmacokinetics (PK) of CDH17-directed antibody–drug conjugates (ADC) remain poorly understood. We evaluated the impact of payload selection and target-mediated clearance on CDH17-directed ADCs. Experimental Design: CDH17-directed ADCs carrying either monomethyl auristatin E (MMAE) or the topoisomerase 1 inhibitor exatecan were evaluated in colorectal cancer models with variable P-glycoprotein (P-gp) expression. The effects of P-gp modulation on ADC sensitivity were assessed. CDH17 expression in human tissues was characterized by immunohistochemistry (IHC), and PK studies were performed in cynomolgus monkeys and mice engineered to express human CDH17. Results: CDH17-exatecan ADCs demonstrated greater antitumor activity than CDH17-MMAE ADCs in P-gp–expressing colorectal cancer models. Forced P-gp expression induced resistance to CDH17–MMAE ADCs without affecting sensitivity to CDH17-exatecan ADCs, whereas genetic or pharmacologic inhibition of P-gp restored CDH17–MMAE activity. CDH17 was highly expressed in colorectal cancer and localized to the lateral membranes of gastrointestinal (GI) epithelial cells in normal tissues. In mice expressing human CDH17, CDH17-directed antibodies and ADCs exhibited approximately fourfold faster clearance than in wild-type (WT) mice or cynomolgus monkeys, consistent with substantial target-mediated systemic drug clearance. Conclusions: Together, these findings identify topoisomerase 1 inhibitor payloads, such as exatecan, as advantageous for targeting P-gp–expressing colorectal cancers while highlighting target-mediated clearance and potential on-target, off-tumor toxicity as important translational challenges for CDH17-directed therapeutics and other ADCs targeting antigens with substantial normal tissue expression.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S5: Induction of apoptosis following 48 hr treatment of CLDN6 positive OVCA429 and CLDN6 negative M202 cells with a range of concentrations (50 μg/ml - 0.3658μg/ml) of CLDN6-23-ADC compared to control IgG ADC.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S5: Induction of apoptosis following 48 hr treatment of CLDN6 positive OVCA429 and CLDN6 negative M202 cells with a range of concentrations (50 μg/ml - 0.3658μg/ml) of CLDN6-23-ADC compared to control IgG ADC.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S8. A. Layout of tissues and B. Scanned whole-slide image of BN1021, normal human tissue microarray stained for CLDN6 expression showing no staining.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S8. A. Layout of tissues and B. Scanned whole-slide image of BN1021, normal human tissue microarray stained for CLDN6 expression showing no staining.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S2: Amino acid sequence alignment of CLDN6 (P56747) and CLDN9 (O95484) with the extracellular loops highlighted
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S2: Amino acid sequence alignment of CLDN6 (P56747) and CLDN9 (O95484) with the extracellular loops highlighted
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S7. CLDN6 expression in ovarian and endometrial cancer tissue samples.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S7. CLDN6 expression in ovarian and endometrial cancer tissue samples.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S4: Binding of CLDN6-23-ADC (5 μg/ml) in artificial cell lines overexpressing CLDN3, CLDN4, CLDN6 or CLDN9 by flow cytometry.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S4: Binding of CLDN6-23-ADC (5 μg/ml) in artificial cell lines overexpressing CLDN3, CLDN4, CLDN6 or CLDN9 by flow cytometry.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S3. A, Efficacy of anti-CLDN6 mouse antibodies in CLDN6 positive OV90 ovarian cancer cell line xenografts. B, Efficacy in CLDN6 positive UMUC4 bladder cancer cell line xenografts. C, No efficacy in CLDN6 negative M202 melanoma cell line xenografts. All antibodies are dosed at 10 mg/kg QW IV in each study. Errors bars represent SEM of 8 replicate animals per group.
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S3. A, Efficacy of anti-CLDN6 mouse antibodies in CLDN6 positive OV90 ovarian cancer cell line xenografts. B, Efficacy in CLDN6 positive UMUC4 bladder cancer cell line xenografts. C, No efficacy in CLDN6 negative M202 melanoma cell line xenografts. All antibodies are dosed at 10 mg/kg QW IV in each study. Errors bars represent SEM of 8 replicate animals per group.
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
File containing supplemental data
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables 1 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
File containing supplemental data
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S6: In vivo efficacy of a range of doses of CLDN6-23-ADC in M202 xenograft models. ADC dosing is IV QW as indicated by the arrows
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
Supplemental Figure S6: In vivo efficacy of a range of doses of CLDN6-23-ADC in M202 xenograft models. ADC dosing is IV QW as indicated by the arrows